A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Official Title

A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Brief Summary

      This Phase IIa international multicenter, open-label, uncontrolled study will evaluate the
      safety and pharmacokinetics of rituximab (MabThera/Rituxan) in pediatric participants with
      severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Participants
      will receive rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1,
      8, 15 and 22.

Study Phase

Phase 2

Study Type


Primary Outcome

Percentage of Participants With Adverse Events (AEs), Including Serious AEs

Secondary Outcome

 Pharmacokinetics: Area Under the Concentration-Time Curve From Time 0 to 180 Days (AUC-180) of Rituximab


Granulomatosis With Polyangiitis



Study Arms / Comparison Groups



* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 23, 2013

Completion Date

May 10, 2018

Primary Completion Date

May 10, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of GPA (EULAR/PRINTO/PRES 2008, Ankara criteria for childhood Wegener's
             granulomatosis) or diagnosis of MPA (according to the Chapel Hill Consensus

          -  Newly diagnosed participants or participants with relapsing disease according to the
             following definition:

        The recurrence or new onset of potentially organ- or life-threatening disease (i.e. one or
        more major Birmingham Vasculitis Activity Score for Wegener's Granulomatosis [BVAS/WG]
        items or disease severe enough to require treatment with cyclophosphamide)

          -  For participants of reproductive potential (males and females), use of reliable means
             of contraception throughout the study participation

          -  For all eligible participants mandatory prophylactic treatment for Pneumocystis
             jirovecii infection

        Exclusion Criteria:

          -  Diagnosis of Churg-Strauss syndrome, as defined by the Chapel Hill Consensus

          -  Limited disease that would not normally be treated with cyclophosphamide

          -  Severe disease requiring mechanical ventilation due to alveolar hemorrhage

          -  Requirement for plasmapheresis or dialysis at screening

          -  Incomplete recovery from recent surgery or less than (<) 12 weeks since surgery prior
             to baseline or planned within 24 weeks of baseline

          -  Lack of peripheral venous access

          -  Pregnancy or breast-feeding

          -  Evidence of other significant uncontrolled concomitant disease, or of disorder or
             condition that, in the investigator's opinion, would preclude or interfere with
             participation of participant

          -  Primary or secondary immunodeficiency (history of or currently active), including
             known history of human immunodeficiency virus (HIV) infection

          -  Evidence of active tuberculosis (participants receiving chemoprophylaxis for latent
             tuberculosis infection are eligible for the study)

          -  Known active infection of any kind (excluding fungal infections of nail beds), or any
             major episode of infection requiring hospitalization or treatment with IV
             anti-infective agents within 4 weeks of baseline or completion of oral anti-infective
             agents within 2 weeks prior to baseline. Entry into this study may be reconsidered
             once the infection has fully resolved

          -  History of deep space/tissue infection within 24 weeks prior to baseline

          -  History of serious recurrent or chronic infection

          -  History of cancer (except for basal cell and squamous cell carcinoma of the skin that
             have been excised and cured)

          -  Currently active alcohol or drug abuse or history of alcohol or drug abuse

          -  History of severe allergic or anaphylactic reaction to a biologic agent or known
             hypersensitivity to any component of rituximab or to murine proteins

          -  Treatment with rituximab or other biologic B cell-targeted therapy (e.g., anti-
             Cluster of Differentiation [CD] 19, anti-CD20, anti-CD22, or anti-B-lymphocyte
             stimulator [BLys]/B-cell activating factor [BAFF]) within 6 months prior to baseline

          -  Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator

          -  Previous treatment with other cell-depleting therapies, including, but not limited to,
             investigational agents (e.g., alemtuzumab, anti-CD4, anti-CD5, anti-CD3, and

          -  Receipt of oral or IV cyclophosphamide within the previous 4 months prior to the
             baseline visit

          -  Receipt of infliximab within 3 months, adalimumab within 2 months or etanercept within
             1 month prior to the baseline visit

          -  Treatment with any investigational agent within 28 days of baseline or 5 half-lives of
             the investigational drug (whichever is longer)

          -  Receipt of any live attenuated vaccine within 28 days prior to baseline

          -  Intolerance or contraindications to IV glucocorticoids

          -  Positive serum human chorionic gonadotropin measured at screening or a positive
             pregnancy test prior to the first rituximab infusion for participants of childbearing

          -  Positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody
             (HBcAb), hepatitis B virus (HBV), or hepatitis C serology

          -  Level of Immunoglobulin (Ig) M below lower limit of normal of age-specific reference

          -  Level of IgG below 5.65 milligram per milliliter

          -  Absolute neutrophil count < 1.5 × 10^3 per microliter and platelet count < 130 × 10^3
             per microliter

          -  Estimated Glomerular Filtration Rate < 15 milliliter per minute per 1.73 m^2

          -  Alanine aminotransferase or aspartate aminotransferase levels greater than 2.5 times
             the upper limit of normal (for age and sex) that cannot be attributed to underlying
             granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)




2 Years - 17 Years

Accepts Healthy Volunteers



Clinical Trials, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Hoffmann-La Roche

Study Sponsor

Clinical Trials, Study Director, Hoffmann-La Roche

Verification Date

June 2019